Clinical Trials Logo

Active Ulcerative Colitis clinical trials

View clinical trials related to Active Ulcerative Colitis.

Filter by:
  • None
  • Page 1

NCT ID: NCT03235752 Completed - Clinical trials for Active Ulcerative Colitis

Safety and Efficacy of TJ301 IV in Participants With Active Ulcerative Colitis

Start date: February 6, 2018
Phase: Phase 2
Study type: Interventional

This is a multicenter, randomized, double-blind, placebo-controlled phase II study.

NCT ID: NCT02748590 Completed - Clinical trials for Active Ulcerative Colitis

Evaluation of Sacral Neuromodulation (SNM) in the Treatment of Active Ulcerative Colitis (PRIMICISTIM)

PRIMICISTIM
Start date: June 2016
Phase: N/A
Study type: Interventional

Efficacy of ulcerative colitis to induce remission in patients with moderate to severe active ulcerative colitis.

NCT ID: NCT01745770 Completed - Clinical trials for Active Ulcerative Colitis

TID 1000 mg Mesalazine Versus TID 2x500 mg Mesalazine in Active Ulcerative Colitis (UC)

Start date: January 2013
Phase: Phase 3
Study type: Interventional

The purpose of the trial is to proof whether TID 1000 mg mesalazine is non-inferior to TID 2x 500 mg mesalazine in the treatment of patients with acute ulcerative colitis

NCT ID: NCT01257386 Completed - Clinical trials for Active Ulcerative Colitis

Comparative Efficacy and Safety Study in Patients With Active Ulcerative Colitis

Start date: November 2010
Phase: Phase 3
Study type: Interventional

To demonstrate that import Mesalazine (Asacol®) is non-inferior to the reference drug, marketed Mesalazine, regarding the primary endpoint (reduction of UC-DAI score)in patients with active ulcerative colitis (UC) treated for 8 weeks.

NCT ID: NCT00616434 Completed - Clinical trials for Active Ulcerative Colitis

A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis

Start date: May 2008
Phase: Phase 2
Study type: Interventional

The primary objective of the study is to evaluate the clinical activity of interferon beta-1a in participants with moderate to severe ulcerative colitis (UC). Secondary objectives of this study are to determine (i) the safety and tolerability of interferon beta-1a in participants with moderate to severe UC, and (ii) the percentage of participants, with a decrease in the Simple Clinical Colitis Activity Index (SCCAI) score of ≥3 points at Week 8.

NCT ID: NCT00603733 Completed - Clinical trials for Active Ulcerative Colitis

Canadian Active & Maintenance Modified Pentasa Study

CAMMP
Start date: October 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate that the new modified oral extended-release Pentasa® 500mg tablet is at least as efficacious as the currently marketed Pentasa® 500mg tablet in active mild to moderate Ulcerative Colitis and also in maintenance of quiescent disease.